High-density lipoprotein cholesterol and cardiovascular disease in Spanish hypertensive women. The RIMHA study;Colesterol HDL y enfermedad cardiovascular en mujeres hipertensas de España. Estudio RIMHA

Revista Espanola de Cardiologia

Volumn 62, Issue 9, 2009, Pages 1022-1031

  Coca, Antonio ^a   Cea Calvo, Luis ^b   Lozano, José V ^c   Inaraja, Verónica ^b   Fernández Pérez, Cristina ^d   Navarro, Jorge ^c   Bonet, Álvaro ^c   Redón, Josep ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Medical affairs Merck sharp and Dohme ltd   (Spain)

^c Centro de Salud Nazaret   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cardiovascular disease; Cross sectional studies; High density lipoprotein cholesterol; Prevalence; Women

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; PREVALENCE;

EID: 70349251256     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)72100-1     Document Type: Article

References (37)

1. S. Yusuf, S. Reddy, S. Ounpuu, and S. Anand Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization Circulation 104 2001 2746 2753 (Pubitemid 33108145)
2. K.A. Matthews, E. Meilahn, L.H. Kuller, S.F. Kelsey, A.W. Caggiula, and R.R. Wing Menopause and risk factors for coronary heart disease N Engl J Med 321 1989 641 646 (Pubitemid 19221308)
3. K.A. Matthews, L.H. Kuller, K. Sutton-Tyrrell, and Y.-F. Chang Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women Stroke 32 2001 1104 1111 (Pubitemid 32825791)
4. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714 (Pubitemid 8110784)
5. G. Assmann, H. Schulte, A. Von Eckardstein, and Y. Huang Highdensity lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl 1996 S11 S20 (Pubitemid 26268441)
6. M. Chapman Beyond LDL cholesterol reduction: the way ahead in managing dyslipidaemia Eur Heart J 7 Suppl 2005 F56 F62
7. P. Barter, A. Gotto, J. LaRosa, J. Maroni, M. Szarek, and S.M. Grundy HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
8. R.D. Abbott, P.W. Wilson, W.B. Kannel, and W.P. Castelli High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study Atherosclerosis 8 1988 207 211
9. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, and J.D. Knoke, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
10. A. Coca, J. Redón, L. Cea-Calvo, J.V. Lozano, J. Navarro, and C. Fernández-Pérez, et al. Estimated risk of a first stroke and conditioning factors in Spanish hypertensive women. The RIMHA study Blood Press 15 2006 237 244
11. 2003 European Society of Hypertension - European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens. 2003;21:1011-53.
12. P.N. Casale, R.B. Devereux, D.R. Alonso, E. Campo, and P. Kligfield Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings Circulation 75 1987 565 572
13. A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, and M.W. Steffes National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147 (Pubitemid 38129105)
14. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375-414.
15. J.L. Palma Gámiz, I. Conget Donlo, V. Bertomeu González, J.F. Ascaso Gimilio, J.R. González Juanatey, and E. Alegría Ezquerra Prevalencia del síndrome metabólico en pacientes con enfermedad cardiovascular en España: estudio CLYDIA Med Clin (Barc) 128 2007 407 413 (Pubitemid 46649043)
16. J. Navarro, J. Redón, L. Cea-Calvo, J.V. Lozano, C. Fernández-Pérez, and A. Bonet Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study Blood Press 16 2007 20 27 (Pubitemid 46679444)
17. E. Alegría, A. Cordero, M. Laclaustra, A. Grima, M. León, and J.A. Casasnovas Prevalencia del síndrome metabólico en población laboral española: registro MESYAS Rev Esp Cardiol 58 2005 797 806 (Pubitemid 41131489)
18. E. Bruckert, M. Baccara-Dinet, F. McCoy, and J. Chapman High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients Curr Med Res Opin 21 2005 1927 1934 (Pubitemid 41803102)
19. E.S. Ford, W.H. Giles, and W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 2002 356 359 (Pubitemid 34251969)
20. R. Estruch, M.A. Martínez-González, D. Corella, J. Salas-Salvadó, V. Ruiz-Gutiérrez, and M.I. Covas Effects of a Mediterraneanstyle diet on cardiovascular risk factors: a randomized trial Ann Intern Med 145 2006 1 11 (Pubitemid 46780599)
21. H.A. Lakka, D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, and J. Tuomilheto The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716 (Pubitemid 35403784)
22. J. Sundstrom, U. Riserus, L. Byberg, B. Zethelius, and H. Lithell Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study BMJ 332 2006 878 883 (Pubitemid 44365581)
23. G. Schillaci, M. Pirro, G. Vaudo, F. Gemelli, S. Marchesi, and C. Porcellati Prognostic value of the metabolic syndrome in essential hypertension J Am Coll Cardiol 43 2004 1817 1822 (Pubitemid 38622521)
24. S. Bansal, J.E. Buring, N. Rifai, S. Mora, F.M. Sacks, and P.M. Ridker Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 2007 309 316 (Pubitemid 47080485)
25. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308 (Pubitemid 47080484)
26. E. Luengo Biología y metabolismo de las HDL J.R. González-Juanatey Lipoproteínas de alta densidad 2009 Sociedad Española de Cardiología, Grupo Acción Médica Madrid 1 10
27. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab, and A.M. Fogelman Antiinflammatory properties of HDL Circ Res 95 2004 764 772 (Pubitemid 39390578)
28. C. Mineo, H. Deguchi, J.H. Griffin, and P.W. Shaul Endothelial and antithrombotic actions of HDL Circ Res 98 2006 1352 1364 (Pubitemid 43948059)
29. M. Tomás, G. Latorre, M. Sentí, and J. Marrugat [The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis] Rev Esp Cardiol 57 2004 557 569 (Pubitemid 38997113)
30. S.J. Robins, D. Collins, J.T. Wittes, V. Papademetriou, P.C. Deedwania, and E.J. Schaefer Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591 (Pubitemid 32240250)
31. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, and J.S. Morse Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592 (Pubitemid 33126837)
32. B.G. Brown, S.K. Hinckley, and X.Q. Zhao Simultaneous lowdensity lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials Curr Op Lipid 17 2006 631 636
33. Action to Control Cardiovascular Risk in Diabetes: ACCORD. Clinicaltrials.gov, NCT00000620 [citado 1 Oct 2008]. Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT00000620
34. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2- THRIVE. Clinicaltrials.gov, NCT00461630 [citado 1 Oct 2008]. Disponible en: http://www.clinicaltrials.gov/ct/show/NCT00461630?order=1
35. Niacin Plus Statin to Prevent Vascular Events. AIMHIGH. Clinicaltrials.gov, NCT00120289 [citado 1 Oct 2008]. Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT00120289?term=aim-high&rank=1
36. J. Redon, L. Cea-Calvo, J.V. Lozano, J.C. Marti-Canales, J.L. Llisterri, and J. Aznar Blood Pressure and Estimated Risk of Stroke in the Elderly Population of Spain: The PREV-ICTUS Study Stroke 38 2007 1167 1173 (Pubitemid 351688336)
37. J.R. Banegas, F. Rodríguez-Artalejo, L.M. Ruilope, A. Graciani, M. Luque, and J.J. De la Cruz-Troca Hypertension magnitude and management in the elderly population of Spain J Hypertens 20 2002 2157 2164 (Pubitemid 35388233)